Dr. Todd Cohen, VP of Medical Affairs at Myriad Genetics and Dr. Mark Edney, Medical Director at Peninsula Institute for Laparoscopic and Robotic Surgery discuss the evolution of prostate cancer treatment over the years.  

Dr. Edney discusses the limitations of relying solely on clinical pathology for the treatment of localized prostate cancer, and how biomarker testing provides additional information to fully understand how a tumor is behaving on a molecular level. Dr. Edney also provides insight on his personal integration of biomarkers within his practice and why he believes molecular testing is slowly being adopted in the Urology space.  

Listen to other episodes here.